Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01760993 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
A Phase 3 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT01760993 is a Phase 3 study that was terminated before completion, run by Shire. The registered enrollment target is 2 participants.
The verdict
NCT01760993, a Phase 3 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.
Interventions
- DRUG SPD489
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-02-01 |
| Est. Completion | 2013-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01760993
The ClinicalTrials.gov registry entry for NCT01760993 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SPD489 is the first listed.
NCT01760993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01760993 about?
NCT01760993 is a clinical study titled "Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia". The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.
What is the current status of trial NCT01760993?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2013-02-01. Estimated completion is 2013-04-01.
What interventions are being tested in trial NCT01760993?
The interventions under investigation include: SPD489 (DRUG).
Who is sponsoring clinical trial NCT01760993?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.